Literature DB >> 17145820

Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.

Yasuyoshi Miyata1, Takahisa Iwata, Kojiro Ohba, Shigeru Kanda, Masaharu Nishikido, Hiroshi Kanetake.   

Abstract

PURPOSE: The expression of matrix metalloproteinase-7 (MMP-7) correlates with the malignant potential of various tumors and patient survival. We investigated the clinical and prognostic significance of MMP-7 expression in cancer cells and endothelial cells in human renal cell carcinoma (RCC). EXPERIMENTAL
DESIGN: We reviewed tissue samples of 156 patients with RCC who had undergone radical operation. MMP-7 expression was examined by immunohistochemistry. Sections containing MMP-7-positive vessels were also stained for CD34. The density of MMP-7-positive vessels was determined by a computer-aided image analysis system. Multivariate analysis was done to assess relevant variables for invasion, metastasis, and cause-specific survival.
RESULTS: The proportion of MMP-7-expressing tumor cells were significantly higher (P < 0.001) than that of normal cells. MMP-7-positive vessels were considered blood vessels based on staining for CD34, and their density was increased in tumor areas. The proportion of MMP-7-expressing cancer cells and density of MMP-7-positive vessels correlated with grade, pathologic tumor stage, and metastasis. Multivariate analysis showed that MMP-7 expression on cancer cells correlated with pathologic tumor stage only, whereas MMP-7-positive vessel density correlated with metastasis only. The elevated status of MMP-7 in cancer tissues was an independent predictor for cause-specific survival (odds ratio, 8.61; P = 0.040) by multivariate analysis.
CONCLUSIONS: Our results showed that MMP-7 influences tumor progression by regulating invasion and angiogenesis. Multivariate analysis showed that MMP-7 status of cancer tissues was strong predictor of poor prognosis. Our results suggest that MMP-7 targeting treatment may be a potential target against RCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145820     DOI: 10.1158/1078-0432.CCR-06-1626

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  22 in total

1.  Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma.

Authors:  Yozo Mitsui; Hiroaki Shiina; Taku Kato; Shigekatsu Maekawa; Yutaka Hashimoto; Marisa Shiina; Mitsuho Imai-Sumida; Priyanka Kulkarni; Pritha Dasgupta; Ryan Kenji Wong; Miho Hiraki; Naoko Arichi; Shinichiro Fukuhara; Soichiro Yamamura; Shahana Majid; Sharanjot Saini; Guoren Deng; Rajvir Dahiya; Koichi Nakajima; Yuichiro Tanaka
Journal:  Mol Cancer Res       Date:  2017-02-27       Impact factor: 5.852

2.  Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method.

Authors:  Christian Niedworok; Frank vom Dorp; Stephan Tschirdewahn; Herbert Rübben; Henning Reis; Miklos Szucs; Tibor Szarvas
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

Review 3.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

4.  Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Authors:  Martin G Klatt; Daniel J Kowalewski; Heiko Schuster; Moreno Di Marco; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

5.  Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient.

Authors:  Irina K Dimitrova; Jennifer K Richer; Michael C Rudolph; Nicole S Spoelstra; Elaine M Reno; Theresa M Medina; Andrew P Bradford
Journal:  Fertil Steril       Date:  2008-07-30       Impact factor: 7.329

6.  Expression of matrix metalloproteinase-10 in non-metastatic prostate cancer: Correlation with an imbalance in cell proliferation and apoptosis.

Authors:  Sugure Maruta; Yasuyoshi Miyata; Yuji Sagara; Shigeru Kanda; Takahisa Iwata; Shin-Ichi Watanabe; Hideki Sakai; Tomayoshi Hayashi; Hiroshi Kanetake
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

7.  Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer.

Authors:  Taketsugu Yamamoto; Takashi Oshima; Kazue Yoshihara; Teppei Nishi; Hiromasa Arai; Kenji Inui; Takeshi Kaneko; Akinori Nozawa; Hiroyuki Adachi; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  Exp Ther Med       Date:  2012-02-22       Impact factor: 2.447

8.  Extracellular matrix gene expression profiling using microfluidics for colorectal carcinoma stratification.

Authors:  Christopher J Hayes; Catriona M Dowling; Susan Dwane; Mary E McCumiskey; Shona M Tormey; B Anne Merrigan; John C Coffey; Patrick A Kiely; Tara M Dalton
Journal:  Biomicrofluidics       Date:  2016-10-31       Impact factor: 2.800

9.  [Siliconchiptechnology-based MMP-7 analysis in urine: an option for preoperative identification of lymph node metastasis in bladder cancer].

Authors:  T Jäger; S Tschirdewahn; F Vom Dorp; G Piechotta; H Rübben; T Szarvas
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639

10.  22-O-(N-Boc-L-glycine) ester of renieramycin M inhibits migratory activity and suppresses epithelial-mesenchymal transition in human lung cancer cells.

Authors:  Yamin Oo; Justin Quiel Lasam Nealiga; Khanit Suwanborirux; Supakarn Chamni; Gea Abigail Uy Ecoy; Varisa Pongrakhananon; Pithi Chanvorachote; Chatchai Chaotham
Journal:  J Nat Med       Date:  2021-07-21       Impact factor: 2.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.